IL15 and Thrombocytopenia: Although several clinical studies have reported that elevated IL-15 expression correlates with improved patient survival, the administration of IL-15 has caused considerable toxicity including hypotension, fever, and thrombocytopenia in cancer patients, which may further prevent the safety approval of IL-15 [18, 30].